Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ADK | P55263 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | USP1 | O94782 | 1/20 | 0.35 |
| ▸ | USP19 | O94966 | 1/20 | 0.35 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783019 | 0.84 | ADK (0.51) | NPC1RAB9ASMN1; SMN2ADKCNR2 | |
| SCHEMBL5349645 | 0.79 | MMP2 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL655855 | 0.77 | ADK (0.44) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL655127 | 0.77 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL22715102 | 0.75 | APP (0.39) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL29439806 | 0.75 | APP (0.39) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL656817 | 0.75 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL26105897 | 0.69 | MAPK14 (0.40) | ADKUSP1USP19UCHL3MAPK13 | |
| SCHEMBL5368604 | 0.69 | RAB9A (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL20742179 | 0.69 | GSK3B (0.52) | NPC1SMN1; SMN2TSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9730944-B2 | Antiviral activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | disclosed |
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-02-04 | — | — | US | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| US-9193741-B2 | Antiviral activity of bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-11-24 | — | — | US | disclosed |
| EP-2923734-A1 | Purine analogues and their use as immunosuppressive agents | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2015-02-05 | — | — | US | disclosed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | disclosed |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-03-27 | — | — | US | disclosed |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2013-07-25 | — | — | US | disclosed |
| EP-2616077-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-07-24 | — | — | EP | disclosed |
| EP-2575969-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012035423-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-03-22 | — | — | WO | disclosed |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-02-23 | — | — | US | disclosed |
| EP-2405973-A2 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011147753-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010103130-A2 | NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | TPMT, STAT6, IL4 | NPC1 3484/4885RAB9A 1604/4885SMN1; SMN2 4474/4885 |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | TPMT, STAT6, IL4 | NPC1 3484/4885RAB9A 1604/4885SMN1; SMN2 4474/4885 |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | HAVCR2, RNASE1, RNASEH1 | NPC1 203/4885RAB9A 697/4885SMN1; SMN2 662/4885 |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | CCNA1, CCND3, CCND1 | NPC1 2365/4885RAB9A 686/4885SMN1; SMN2 2484/4885 |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | RNASE1, HAVCR2, RNASEH1 | NPC1 117/4885RAB9A 565/4885SMN1; SMN2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.